Meeting
2022 ASCO Annual Meeting
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).
Authors
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center, Houston, TX
Ferdinandos Skoulidis , Mary Weber Redman , Jennifer Marie Suga , Tareq Al Baghdadi , John L. Villano , Sarah B. Goldberg , Liza C Villaruz , Katherine Minichiello , David R. Gandara , Roy S. Herbst , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04173507
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9060)
DOI
10.1200/JCO.2022.40.16_suppl.9060
Abstract #
9060
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.
First Author: Ritesh Kotecha
Poster
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
First Author: Sukhmani Kaur Padda
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko